In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fibrocell Science Inc (FCSC – Research Report), with a price target of $22. The company’s shares closed yesterday at $2.54.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV).”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -3.9% and a 34.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fibrocell Science Inc with a $22 average price target.
Based on Fibrocell Science Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.62 million. In comparison, last year the company had a GAAP net loss of $2.9 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fibrocell Science, Inc. is an autologous cell and gene therapy company, which focuses on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. The company was founded on December 28, 1995 and is headquartered in Exton, PA.